Novavax Global Commercial Operations and COVID-19 Vaccine Update

novavax Strong foundation established in 2022 to support success in 2023+ Progress supports commercial build-out for COVID-19 vaccine and readiness for future product launches Commercialized COVID-19 vaccine with strong safety, efficacy, and storage profile Developed commercial presence in priority markets (Americas, EU, and APAC) Received authorizations in 40+ countries for COVID-19 vaccine Built global manufacturing network to enable sustainable capacity ☑ Established vaccine distribution globally to support broad market access Engaged with public and private decision-makers to prepare for market in 2023+ © 2023 NOVAVAX. All rights reserved. a

View entire presentation